HTA

Summary of Expensive Drugs for Rare Diseases (EDRD) Working Group Webinar   Signals Decoded:   Stakeholder consultation is underway on a supplemental process for complex/specialized drugs that builds upon the existing national HTA and reimbursement process to make responsive funding decisions with a focus on non-oncology therapies. The supplemental process is a significant development in EDRD policy and it looks to streamline the evaluation and reimbursement process of eligible drugs … Read More →

Panel 5: Patient Support Programs   Panel Description: This session will help participants develop a better understanding of why PSPs are well-suited to support the development of outcomes-based agreements. It will suggest effective ways that PSPs can be developed to support data collection for HTA. Finally, current pCPA perspectives on PSPs and the opportunity for data collection within programs will be explored by this panel. Moderator: Allison Wills Panellists: Sang … Read More →

Panel 3: Health Technology Assessment   Panel Description: Canada’s centralized HTA agency, CADTH, has recently released a new 3-year strategic plan that marks a shift from its previous vision. Noteworthy is the focus of recommendations on alignment of drug assessment with the priorities of the participating plans over all phases of the technology life cycle. Join us to hear CADTH describe their new strategic plan, how their mandate has evolved, … Read More →

On September 13th, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued details on a new CADTH and Institut national d’excellence en santé et en services sociaux (INESSS) pilot project to jointly engage with clinical specialists. According to CADTH’s communication, the objectives of the pilot project are to: Strengthen the current pharmaceutical review processes used by CADTH and INESSS with respect to engagement with Canadian clinical specialists. … Read More →

A Comparison of Proposed INESSS and Current CADTH Evaluation Fees   On February 21, 2018, the Quebec government released draft regulations (Gazette Officielle du Québec) that outline fees payable to Institut national d’excellence en santé et en services sociaux (INESSS) for the scientific evaluation of a drug or stable blood product. The fees are expected to vary based on the type of dossier submitted for scientific review with INESSS determining … Read More →

The MORSE KEY: Upcoming Events and Conferences   There are a number of conferences/events/deadlines that individuals in market access may be interested in for the upcoming month of September. For more details, please visit the MORSE Key Market Access Events page. Government/Agencies September 15 – CADTH Deadline for Comments on Therapeutic Review Framework September 18 – PMPRB HDAP Meeting September 20 –CDEC Meeting Associations September 11 – 2017 CAPDM MEMBER … Read More →